Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 30 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

27%

8 trials in Phase 3/4

Results Transparency

36%

5 of 14 completed with results

Key Signals

5 with results100% success

Data Visualizations

Phase Distribution

21Total
Not Applicable (5)
Early P 1 (1)
P 1 (4)
P 2 (3)
P 3 (5)
P 4 (3)

Trial Status

Completed14
Active Not Recruiting6
Recruiting4
Unknown3
Not Yet Recruiting2
Withdrawn1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 14 completed trials

Clinical Trials (30)

Showing 20 of 20 trials
NCT07282847Phase 1Recruiting

A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late Onset Pompe Disease (PROGRESS-GT LOPD)

NCT00567073Recruiting

Pompe Pregnancy Sub-Registry

NCT06150820Not ApplicableActive Not RecruitingPrimary

A Study About Antibody Levels and Biomarkers in the Blood in People With Late-onset Pompe Disease

NCT07478172Not ApplicableRecruiting

Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease

NCT04138277Phase 3CompletedPrimary

A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)

NCT04174105Phase 1Active Not RecruitingPrimary

Gene Transfer Study in Patients With Late Onset Pompe Disease

NCT03911505Phase 3Active Not RecruitingPrimary

ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD

NCT03694561Active Not Recruiting

Developing a Management Approach for Patients With "Late-Onset" Pompe Disease

NCT03729362Phase 3CompletedPrimary

A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease

NCT04929002Active Not Recruiting

Carbon-13 Magnetic Resonance Spectroscopy in Glycogen Storage Diseases

NCT06391736Phase 1RecruitingPrimary

Evaluation of the Safety and Efficacy of Late-onset Pompe Disease Gene Therapy Drug

NCT05083806Not ApplicableCompleted

MSOT in Pompe Disease

NCT04093349Phase 1Active Not Recruiting

A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)

NCT06575829Phase 4Not Yet RecruitingPrimary

Treatment Frequency Reduction in Pompe Disease

NCT06178432Early Phase 1Not Yet RecruitingPrimary

Evaluation of the Safety, Tolerability and Efficacy of Gene Therapy Drug for Late Onset Pompe Disease (LOPD)

NCT05272969UnknownPrimary

Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease

NCT05951790Not ApplicableUnknown

Inspiratory Muscle Training (IMT) in Adult People With Pompe Disease

NCT03893240Not ApplicableCompleted

Neutralizing Antibody Seroprevalence Study With a Retrospective Component in Participants With Late-Onset Pompe Disease

NCT04120168Completed

Study Determining the Frequency of Duchenne Muscular Dystrophy and Late-onset Pompe Disease

NCT04907162CompletedPrimary

Musculoskeletal Nociceptive Pain in Participants With Neuromuscular Disorders

Scroll to load more

Research Network

Activity Timeline